1-20 of 264
Tapan M. Kadia, MD
Close
Sort by
Journal Articles

Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia

Guillermo Montalban Bravo, MD, Rashmi Kanagal-Shamanna, MD, Koji Sasaki, MD, Lucia Masarova, MD, Kiran Naqvi, MD MPH, Elias Jabbour, MD, Courtney D. DiNardo, MD MSCE, Koichi Takahashi, MD PhD, Marina Konopleva, MD PhD, Naveen Pemmaraju, MD, Nicholas J. Short, MD, Ghayas C. Issa, MD, Tapan M. Kadia, MD, Farhad Ravandi, MBBS, Naval Daver, MD, Gautam Borthakur, MD, Zeev E. Estrov, MD, Joseph D. Khoury, MD, Sanam Loghavi, MD, Sherry A. Pierce, BSN, BA, Carlos E. Bueso-Ramos, MD PhD, Keyur Patel, MD PhD, Srdan Verstovsek, MD PhD, Hagop M. Kantarjian, MD, Prithviraj Bose, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 54–56.
https://doi.org/10.1182/blood-2020-137176
Published: 2020
Journal Articles

Activity of Venetoclax-Based Therapy in CMML and CMML with Blast Transformation

Danielle Hammond, MD, Courtney D. DiNardo, MD MSCE, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Jorge M. Ramos Perez, MD, Veronica A Guerra, MD, Rashmi Kanagal-Shamanna, MD, Shilpa Paul, PharmD, Kiran Naqvi, MD MPH, Koji Sasaki, MD, Elias Jabbour, MD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Farhad Ravandi, MBBS, Naval Daver, MD, Zeev E. Estrov, MD, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Guillermo Montalban-Bravo, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–37.
https://doi.org/10.1182/blood-2020-136385
Published: 2020
Journal Articles

Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study

Prithviraj Bose, MD, Naveen Pemmaraju, MD, Lucia Masarova, MD, Sharon D. Bledsoe, Naval Daver, MD, Elias Jabbour, MD, Tapan M. Kadia, MD, Zeev E. Estrov, MD, Steven M. Kornblau, MD, Michael Andreeff, MD PhD, Jorge E. Cortes, MD, Nitin Jain, MD, Gautam Borthakur, MD, Yesid Alvarado, MD, Julie Huynh-Lu, Physician Assistant, Madeleine Nguyen-Cao, Physician Assistant, Mary Ann Richie, Mackenzie H. Dobbins, Lingsha Zhou, Sherry A. Pierce, BSN, BA, Xuemei Wang, MS, Allison M. Pike, RN, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 10–11.
https://doi.org/10.1182/blood-2020-140441
Published: 2020
Journal Articles

Long-Term Outcome of Low-Dose Hypomethylating Agents in Lower-Risk Myelodysplastic Syndromes: A Randomized Phase 2 Study

Koji Sasaki, MD, Elias Jabbour, MD, Guillermo Montalban Bravo, MD, Nicholas J. Short, MD, Rashmi Kanagal-Shamanna, MD, Tapan M. Kadia, MD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Jorge E. Cortes, MD, Farhad Ravandi, MBBS, Yesid Alvarado, MD, Kelly S. Chien, MD, Hui Yang, MD PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 46–47.
https://doi.org/10.1182/blood-2020-139817
Published: 2020
Journal Articles

The Addition of Venetoclax to Ibrutinib Achieves a High Rate of Undetectable Minimal Residual Disease in Patients with High-Risk CLL

Philip A. Thompson, MB, MS, Alessandra Ferrajoli, MD, Nitin Jain, MD, Yan Wang, Christine B Peterson, Naveen Garg, MD, Chongjuan Wei, PhD, Ana Ayala, RN, Tapan M. Kadia, MD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Nicholas J. Short, MD, Michael J. Keating, MBBS, William G. Wierda, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–29.
https://doi.org/10.1182/blood-2020-141716
Published: 2020
Journal Articles

Ibrutinib Induces Durable Remissions in Treatment-Naïve CLL Patients with 17p Deletion/TP53 Mutations: Five Year Follow-up from a Phase 2 Study

Mariela Sivina, Nitin Jain, MD, Ekaterina Kim, PhD, Tapan M. Kadia, MD, Zeev E. Estrov, MD, Maro Ohanian, DO, Michael Andreeff, MD PhD, Mathew Thomas, Philip A. Thompson, MB, MS, Hagop M. Kantarjian, MD, Michael J. Keating, MBBS, Susan M. O'Brien, MD, William G. Wierda, MD PhD, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-141014
Published: 2020
Journal Articles

Risk Factors Associated with 30-Day Unplanned Readmissions for Adult Acute Lymphoblastic Leukemia (ALL)

Veronica A Guerra, MD, Yasmin Alwash, MD, Yan Yuanqing, PhD, Jorge M. Ramos Perez, MD, Guillaume Richard-Carpentier, MD, Ahmad S. Alotaibi, MD, Hycienth O Ahaneku, MD MPH, PhD, Bachar Samra, MD, Arrvind Raghunath, MD, Nitin Jain, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Gautam Borthakur, MD, Alessandra Ferrajoli, MD, Koji Sasaki, MD, Steven M. Kornblau, MD, Zeev E. Estrov, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Tapan M. Kadia, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-142055
Published: 2020
Journal Articles

Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis

Kiyomi Morita, MDPhD, Koji Sasaki, MD, Guillaume Richard-Carpentier, MD, Marina Konopleva, MD PhD, Xuelin Huang, PhD, Nicholas J. Short, MD, Nitin Jain, MD, Farhad Ravandi, MBBS, Bouthaina S. Dabaja, MD, Naval Daver, MD, Tapan M. Kadia, MD, Yesid Alvarado, MD, Courtney D. DiNardo, MD MSCE, Ghayas C. Issa, MD, Naveen Pemmaraju, MD, Guillermo Garcia-Manero, MD, Srdan Verstovsek, MD PhD, Sa A Wang, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Richard E. Champlin, MD, Issa F. Khouri, MD, Partow Kebriaei, MD, Heather M. Schroeder, Maria Khouri, Koichi Takahashi, MD PhD, Susan M. O'Brien, MD, Hagop M. Kantarjian, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–43.
https://doi.org/10.1182/blood-2020-142121
Published: 2020
Journal Articles

Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Patrick K Reville, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD, Musa Yilmaz, MD, Guillermo Montalban-Bravo, MD, Courtney D. DiNardo, MD MSCE, Michael Andreeff, MD PhD, Naval Daver, MD, Nitin Jain, MD, Steven M. Kornblau, MD, Elias Jabbour, MD, Nicholas J. Short, MD, Yesid Alvarado, MD, Maro Ohanian, DO, Prithviraj Bose, MD, Lucia Masarova, MD, Sa A Wang, MD, Rebecca S. S Tidwell, MS, Zeev E. Estrov, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD PhD, Farhad Ravandi, MBBS, Tapan M. Kadia, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–9.
https://doi.org/10.1182/blood-2020-141075
Published: 2020
Journal Articles

Clinical Course, Outcomes and Genetic Characterization of Patients with Isolated Myeloid Sarcoma

Hussein A Abbas, MDPhD, Patrick K Reville, MD, Alexis Geppner, Maro Ohanian, DO, Koji Sasaki, MD, Gautam Borthakur, MD, Naval Daver, MD, Courtney D. DiNardo, MD MSCE, Carlos E. Bueso-Ramos, MD PhD, Michael Andreeff, MD PhD, Nicholas J. Short, MD, Sherry A. Pierce, BSN, BA, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD PhD, Farhad Ravandi, MBBS, Hagop M. Kantarjian, MD, Tapan M. Kadia, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 25–26.
https://doi.org/10.1182/blood-2020-138459
Published: 2020
Journal Articles

Outcomes of Chronic Myelomonocytic Leukemia (CMML) after Hypomethylating Agent (HMA) Failure

Veronia Guerra, Jorge M. Ramos Perez, MD, Danielle Hammond, MD, Kelly S. Chien, MD, Rashmi Kanagal-Shamanna, MD, Kiran Naqvi, MD MPH, Koji Sasaki, MD, Shilpa Paul, PharmD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSCE, Marina Konopleva, MD PhD, Naval Daver, MD, Farhad Ravandi, MBBS, Naveen Pemmaraju, MD, Nicholas J. Short, MD, Ghayas C. Issa, MD, Koichi Takahashi, MD PhD, Zeev E. Estrov, MD, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Guillermo Montalban Bravo, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-139901
Published: 2020
Journal Articles

Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial

Abhishek Maiti, MBBS, Elias Jabbour, MD, Nitin Jain, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Jan A. Burger, MD PhD, William G. Wierda, MD PhD, Marina Konopleva, MD PhD, Yesid Alvarado, MD, Nicholas J. Short, MD, Stefan Faderl, Susan M. O'Brien, MD, Alessandra Ferrajoli, MD, Steven M. Kornblau, MD, Naval Daver, MD, Naveen Pemmaraju, MD, Prithviraj Bose, MD, Philip A. Thompson, MB, MS, Joseph D. Khoury, MD, Hayley Balkin, Mary Kelly, Hind Azzawi, Rebecca Garris, MSc, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–39.
https://doi.org/10.1182/blood-2020-136873
Published: 2020
Journal Articles

Adoptive Therapy with Allogeneic Cord Blood T Regulatory Cells Show Safety and Early Clinical Signal in Primary Myelofibrosis

Tapan M. Kadia, MD, Naveen Pemmaraju, MD, Musa Yilmaz, MD, Li Li, MD, Mi-Ae Lyu, PhD, Meixian Huang, MD,PhD, Ke Zeng, MD, Simrit Parmar, MD, MSCI, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Ghayas C. Issa, MD, Elias Jabbour, MD, Gautam Borthakur, MD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–42.
https://doi.org/10.1182/blood-2020-138585
Published: 2020
Journal Articles

Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Nicholas J. Short, MD, Partow Kebriaei, MD, Xuelin Huang, PhD, Nitin Jain, MD, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Richard E. Champlin, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD PhD, Naval Daver, MD, Hind Rafei, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Maria R Khouri, Jovitta Jacob, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–42.
https://doi.org/10.1182/blood-2020-139896
Published: 2020
Journal Articles

A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Nicholas J. Short, MD, Partow Kebriaei, MD, Xuelin Huang, PhD, Nitin Jain, MD, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Richard E. Champlin, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD PhD, Hind Rafei, MD, Sa A Wang, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Maria Khouri, Jovitta Jacob, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–4.
https://doi.org/10.1182/blood-2020-140037
Published: 2020
Journal Articles

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Nitin Jain, MD, Bouthaina S. Dabaja, MD, Yesid Alvarado, MD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Serena Chew, PharmD, Guillermo Garcia-Manero, MD, Jan A. Burger, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Maro Ohanian, DO, Maria Khouri, Philip A. Thompson, MB, MS, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–38.
https://doi.org/10.1182/blood-2020-143386
Published: 2020
Journal Articles

Roleof Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Richard E. Champlin, MD, Nitin Jain, MD, Bouthaina S. Dabaja, MD, Ghayas C. Issa, MD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Nadya Jammal, PharmD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Rita Khouri, Patrice Nasnas, MD, Philip A. Thompson, MB, MS, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–41.
https://doi.org/10.1182/blood-2020-143286
Published: 2020
Journal Articles

Biomarker Driven Umbrella Trial of Crenolanib in Combination with Ivosidenib, Enasidenib, Venetoclax, Vyxeos and/or Salvage Chemotherapy in FLT3 Mutant AML

Naval Daver, MD, Aaron D Goldberg, MDPhD, Courtney D. DiNardo, MD MSCE, Tapan M. Kadia, MD, Eunice S. Wang, MD, Richard M. Stone, MD, Han Zhang, MD PhD, Boo Messahel, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–17.
https://doi.org/10.1182/blood-2020-140378
Published: 2020
Journal Articles

Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, C. Cameron Yin, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Nitin Jain, MD, Koichi Takahashi, MD PhD, Bouthaina S. Dabaja, MD, Srdan Verstovsek, MD PhD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Caitlin R. Rausch, PharmD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Patrice Nasnas, MD, Rita Khouri, Monica Kwari, BSN, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–47.
https://doi.org/10.1182/blood-2020-143401
Published: 2020
Journal Articles

Interim Results of an Open-Label Phase IB/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-PDL1 Mab, Smoothened Inhibitor, Anti-CD33 Mab, Bcl-2 Inhibitor, and Azacitidine As Single-Agents and As Combinations for Relapsed/Refractory Acute Myeloid Leukemia

Nicholas J. Short, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSCE, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Koji Sasaki, MD, Ghayas C. Issa, MD, Guillermo Montalban-Bravo, MD, Prithviraj Bose, MD, Jan A. Burger, MD PhD, Darla Miller, Lynette Alexander-Williams, Farhad Ravandi, MBBS, Marina Konopleva, MD PhD, Hagop M. Kantarjian, MD, Naval Daver, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–23.
https://doi.org/10.1182/blood-2020-140153
Published: 2020